CORONA Remedies (CORONA) Investor presentation summary

Q2 and H1 FY27 performance

• Q2 revenue INR 441.2 Cr, up 22.2% YoY; EBITDA INR 96.0 Cr, up 22.3%, with a 21.7% margin.

• H1 revenue INR 863.6 Cr, up 22.0% YoY; EBITDA INR 189.1 Cr, up 27.5%, with margin rising to 21.9% from 20.9%.

• H1 PAT INR 120.4 Cr, up 22.2%; Q2 PAT rose 15.3% to INR 60.3 Cr, with lower Q2 PAT margin reflecting higher D&A from new facilities and acquired brands.

• H1 net cash from operations was INR 112.7 Cr versus INR 113.4 Cr; net debt/(cash) was reported at (INR 53.9 Cr).

Business mix and market position

• India contributed 97.1% of H1 FY27 revenue; chronic and sub-chronic therapies contributed 72.1%.

• Domestic sales growth was 22.5% in Q2 FY27 versus 12.0% for IPM; MAT Sep-23 to Sep-26 growth was 16.9% versus 8.1%.

• Improved IPM rank to 26th in MAT Sep-26 from 27th in MAT Mar-26; rank rose 6 places over three years.

• 33 engine brands generated ~79% of domestic sales and ~22% CAGR over MAT Sep-23 to MAT Sep-26; four brands exceeded INR 100 Cr annual sales, including one above INR 200 Cr.

• Therapy ranks in addressable markets at MAT Sep-26: Women's Healthcare #5, Pain Management #5, Urology #12 and Cardio-Diabeto #19.

Manufacturing and quality

• Installed annual capacity totals 1.84 Bn formulation units, 20 Mn sachets, 10 Mn liquid bottles and 1.5 Mn ointments/gels.

• Bhayla's OSD line renewed EU-GMP certification in May 2026; the hormone facility began operations with EU-GMP certification in June and received ANVISA GMP certification in October.

• Gujarat facilities hold EU-GMP, EAEU, WHO-GMP, Uzbekistan GMP and ANVISA certifications; Himachal Pradesh facility holds WHO-GMP and Uganda NDA certifications.

• Two DSIR-approved R&D facilities are located within manufacturing sites; an additional 400 Mn tablets of commercial production began at Gujarat in December 2025.